Improving stroke prevention in patients with atrial fibrillation

Trials

Henk CPM van Weert⁴  Saeid Eslami²  Ron JG Peters¹  Harry R Büller⁵  Ameen Abu-Hanna³  Derk L Arts³ 

[1] Department of Cardiology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands;Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran;Department of Medical Informatics, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands;Department of General Practice, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands;Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

关键词: General practice;    Clinical decision support system;    Anti-thrombotic treatment;    Stroke prevention;    Decision support;    Atrial fibrillation;   

Others  :  1093568
DOI  :  10.1186/1745-6215-14-193

 received in 2012-11-19, accepted in 2013-06-25,  发布年份 2013

【 摘 要 】

Background

Patients with atrial fibrillation (AF) are at increased risk for stroke. Antithrombotic treatment reduces this risk. Antithrombotic treatment consists of either administration of oral anticoagulants (OAC) or the provision of an antiplatelet drug. International guidelines provide advice on the preferred treatment, thereby balancing the risks and benefits of OAC. However, adherence to these guidelines is reported to be as low as 50%. There is paucity in research on why adherence rates are low. Recent studies have shown decision support systems can improve guideline adherence. We investigate the use of a clinical decision support system to improve guideline adherence among general practitioners (GPs) treating patients with AF and study reasons for guideline non-adherence.

Methods/Design

The study is a randomized controlled trial, which is performed among Dutch general practitioners. Initially, GPs in the vicinity of the Academic Medical Center (AMC) in Amsterdam will be included, after which other practices will be recruited. We have developed a novel decision support system that displays a list with pending messages for the on-screen medical record in real time. Messages are generated on a server that evaluates a decision rule based on the atrial fibrillation guideline of the Dutch College of General Practitioners. By interacting with the list, messages can be opened for a description and explanation, or be ignored. GPs are allocated into three groups: 1) control group; 2) intervention group A, in which messages can be ignored without justification; and 3) intervention group B, in which messages can only be ignored with justification.

Our main outcome measure is the between-group difference in the proportion of patients receiving antithrombotic prescriptions in adherence to the Dutch GP guideline for atrial fibrillation. Secondary outcomes are reasons GPs state for deviating from the guideline and the effect on guideline adherence of requiring justification when ignoring a message.

Discussion

This paper describes the protocol for a cluster randomized trial to study the effects of a clinical decision support system in patients with atrial fibrillation. The system is characterized by a non-interruptive presentation and real-time messages that are updated after each relevant action the GP performs.

Trial registration

This trial is registered with the Dutch Trial Register under registration number 3570.

【 授权许可】

   
2013 Arts et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991, 22:983-988.
• [2]Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB: Stroke severity in atrial fibrillation. The Framingham study. Stroke 1996, 27:1760-1764.
• [3]Hart RG, Pearce LA, Aguilar MI: Meta-analysis antithrombotic therapy to prevent stroke in patients who have novalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
• [4]Ogilvie IM, Welner SA, Cowell W, Lip GY: Ischaemic stroke and bleeding rates in ‘real-world’ atrial fibrillation patients. Thromb Haemost 2011, 106:34-44.
• [5]Dinh T, Nieuwlaat R, Tieleman RG, Buller HR, van Charante NA, Prins MH, Crijns HJ: Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in The Netherlands–The EXAMINE-AF study. A questionnaire survey. Int J Clin Pract 2007, 61:24-31.
• [6]Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt G, Le Heuzey JY, Prins MH, Lévy S, Crijns HJ, European Heart Survey Investigators: Atrial fibrillation management: a prospective survey in ESC Member Countries - The Euro heart survey on atrial fibrillation. Eur Heart J 2005, 26:2422-2434.
• [7]Ogilvie IM, Welner SA, Cowell W, Lip GY: Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation. Am J Cardiol 2011, 108:151-161.
• [8]Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH: Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999, 282:1458-1465.
• [9]Bright TJ, Wong A, Dhurjati R, Bristow E, Bastian L, Coeytaux RR, Samsa G, Hasselblad V, Williams JW, Musty MD, Wing L, Kendrick AS, Sanders GD, Lobach D: Effect of clinical decision-support systems: a systematic review. Ann Intern Med 2012, 157:29-43.
• [10]Kawamoto K, Houlihan CA, Balas EA, Lobach DF: Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. BMJ 2005, 330:765.
• [11]WONCA: Report of the Classification Committee of the World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians (WONCA). J Fam Pract 1981, 13:671-681.
• [12]Opstelten W, Boode BS, Heeringa J, Rutten FH, Goudswaard AN: Summary of the practice guideline ‘Atrial fibrillation’ (first revision) from the Dutch College of General Practitioners. Ned Tijdschr Geneeskd 2010, 154:A1570.
• [13]Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke. JAMA 2001, 285:2864-2870.
• [14]Campbell MKGJ, Steen N: For the changing professional pratice in Europe group: sample size calculations for cluster randomised trials. J Health Serv Res Policy 2000, 5:12-16.
• [15]Medlock S, Opondo D, Eslami S, Askari M, Wierenga P, de Rooij SE, Abu-Hanna A: LERM (Logical Elements Rule Method): a method for assessing and formalizing clinical rules for decision support. Int J Med Inform 2011, 80:286-295.
• [16]Ardery G, Carter BL, Milchak JL, Bergus GR, Dawson JD, James P, Franciscus C, Kim Y: Explicit and implicit evaluation of physician adherence to hypertension guidelines. J Clin Hypertens (Greenwich, Conn) 2007, 9:113-119.